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ity of effective treatments for PMLS is an important ad­
vance. In contrast to the situation a decade ago, there 
are now treatments for PMS that have stood the test of 
rigorous trials and that enable us to reduce the consid­
erable suffering of women with this disorder. Although 
we have not identified the source of the “sensitivity” de­
scribed by von Feuchtersleben, at least we are finally 
rediscovering the fact that it exists.
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THE CLINICAL IMPORTANCE OF THE 
URINARY EXCRETION OF AQUAPORIN-2
T h e  movement of water across the cell membranes 
of an organism is of central importance in many func­
tions. The notion that the permeability of some tissues 
to water is too great to be accounted for by lipid-medi­
ated diffusion has been ccntral to the development of 
the concept of channel-mediated water transport. De­
spite the general acceptance of the existence of water- 
channel proteins, their molecular identification has 
long remained elusive. The first water-channel protein, 
originally known as CHIP28 (an acronym for channel- 
forming integral membrane protein of 28 kd), was dis­
covered during studies of erythrocyte blood-group pro­
teins.1 Its expression in xenopus oocytes results in a 
30-fold increase in osmotic permeability to water but in 
no increase in permeability to ions.2
At present, five structurally related mammalian wa- 
ter-channcl proteins have been identified, named aqua- 
porin-1 through aquaporin-5. In view of the large quan­
tity of water filtered and reabsorbed in mammalian 
kidneys, it is not surprising that aquaporins play an im­
portant part in the renal handling of water, Aquaporins
1, 2, and 3 are highly expressed in the kidney,1,3,4 aqua- 
porin-4 is expressed most abundantly in the brain,5 and 
aquaporin-5 is most prominent in salivary, lacrimal, 
and respiratory tissues,h In the kidney, aquaporin-1 
(the former CHIP28) is responsible for the constitutive- 
ly high permeability to water of the proximal tubule 
and the thin descending limb of Henle’s loop.1 It was 
therefore surprising that persons homozygous for mu­
tations in the aquaporin-1 gene resulting in the lack 
of aquaporin-I water channels were clinically normal.7 
The only explanation for the normal clinical phenotype 
in such persons seems to be the existence of another 
mechanism, one capable of compensating for the ab­
sence of functional aquaporin-1 proteins.
Aquaporin-2, the vasopressin-regulated water chan­
nel in the collecting duct, has a primary role in concen­
trating the urine. An increase in serum osmolality or a 
decrease in circulating volume leads to the secretion of 
arginine vasopressin from the neurohypophysis. The 
binding of vasopressin to vasopressin V2 receptors in 
the principal cells of the cortical collecting duct and 
cells in the inner medullary collecting duct triggers 
a cyclic-AMP—dependent chain of events that results 
in increased reabsorption of water. Aquaporin-2 resides 
in intracytoplasmic vesicles in these cells. The binding 
of vasopressin to its receptors promotes the insertion of 
these aquaporin-2—containing vesicles into the normal­
ly watertight luminal membrane, increasing the perme­
ability of the membrane to water. When stimulation by 
vasopressin is terminated, aquaporin-2 is removed from 
the luminal membrane by endocytosis of the vesicles. 
This controlled movement of aquaporin-2-containing 
vesicles between the lum inal membrane and the cy­
toplasm is known as the “membrane shuttle” mecha­
nism. The efflux of water at the basolateral membrane 
of collecting-duct cells appears to be mediated by aqua-
porin-3.4
The link between aquaporin-2 and the regulation of 
the renal excretion of water by vasopressin was firmly 
established when it was discovered that the aquaporin- 
2 gene is mutated in patients with congenital nephro­
genic diabetes insipidus. This hereditary renal disease 
is characterized by insensitivity of the collecting-duct 
cells to the antidiuretic effect of vasopressin. As a re­
sult, the kidney loses its concentrating ability and the 
patient excretes large volumes of hypotonic urine, a 
condition that may lead to severe dehydration. In most 
families, nephrogenic diabetes insipidus is caused by a 
mutation in the gene for the vasopressin V2 receptor on 
the X  chromosome, resulting in an X-linked recessive 
mode of inheritance. In some patients, however, neph­
rogenic diabetes insipidus is inherited as an autosomal 
trait. Recently, mutations in the autosomal gene coding 
for aquaporin-2 were found in four patients with neph­
1576 THE NEW ENGLAND JOURNAL OF MEDICINE June 8, 1995
rogenic diabetes insipidus.H Expression studies in xeno- 
pus oocytes showed that the mutated water channels 
are indeed nonfunctional.
In this issue of the Journal\ Kanno et al.,J report that 
aquaporin-2 is detectable in urine in both soluble and 
membrane-bound forms and that the urinary excretion 
of aquaporin-2 reflects the physiologic regulation of 
aquaporin-2 water channels by vasopressin. Thus, dehy­
dration or infusion with the V2 analogue desmopressin 
(l-desamino-8-D-arginine vasopressin, or DDAVP) sig­
nificantly increased the urinary excretion of aquaporin- 
2 in normal subjects. The authors suggest that this in­
crease results from increased delivery of aquaporin-2 to 
the luminal membrane. In five patients with vasopressin 
deficiency (central diabetes insipidus), the basal urinary 
excretion of aquaporin-2 was very low during water 
restriction but was four to six times higher after the 
subcutaneous injection of vasopressin, a finding consis­
tent with the presence of an intact urine-concentrating 
mechanism in the kidney. The increase in the urinary 
excretion of aquaporin-2 after the injection of vasopres­
sin in the patients with central diabetes insipidus prob­
ably resulted from increased expression of aquaporin-2 
in the kidney medulla. In patients with either X-linked 
or autosomal nephrogenic diabetes insipidus, however, 
there was no increase in the urinary excretion of aqua­
porin-2 in response to desmopressin. The authors con­
clude that such excretion can be used as an index of the 
action of vasopressin and may help in differentiating be­
tween nephrogenic and central diabetes insipidus. The 
demonstration of aquaporin-2 in the urine of humans is 
of interest because it indicates that some particulate 
aquaporin-2 is secreted into the lumen, a possibility not 
considered in the membrane-shuttle hypothesis.
The conclusion that measuring urinary aquaporin-2 
excretion may aid in the differential diagnosis of con­
genital diabetes insipidus may be somewhat exaggerat­
ed. In most patients nephrogenic and central diabetes 
insipidus can be differentiated easily by measuring uri­
nary osmolality in response to the intranasal adminis­
tration of desmopressin. Patients with congenital neph­
rogenic diabetes insipidus have no increase in urinary 
osmolality after the administration of desmopressin, 
whereas patients with central diabetes insipidus have a 
substantial increase. Therefore, the measurement of 
aquaporin-2 excretion is not necessary, and in addition 
it is too complicated at present for routine clinical use.
Nevertheless, the possibility of using urinary excre­
tion of aquaporin-2 as an index of the action of vaso­
pressin in the kidney is exciting in view of the recent 
observations that the long-term treatment of rats with 
lithium causes a marked decrease in the expression of 
the aquaporin-2 protein in medullary collecting-duct 
cells and that it results in severe nephrogenic diabetes 
insipidus.10 Thus, lithium-induced nephrogenic diabe­
tes insipidus may be due to the decreased availability of 
aquaporin-2 water channels. It would be interesting to 
know whether there is a decrease in the urinary excre­
tion of aquaporin-2 in patients receiving prolonged lith­
ium treatment, because nephrogenic diabetes insipidus 
develops in approximately 20 percent of patients who 
receive lithium for affective disorders. If so, measuring 
the urinary excretion of aquaporin-2 would be an ele­
gant method of examining whether other forms of sec­
ondary nephrogenic diabetes insipidus, such as those 
caused by tetracyclines, hypokalemia, hypercalcemia, 
juvenile nephronophthisis, or postobstructive diuresis, 
are also associated with reductions in either the expres­
sion of aquaporin-2 or its delivery to the luminal mem­
brane.
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SIGNALING PATHWAYS AND c-fos 
TRANSCRIPTIONAL RESPONSE — LINKS 
TO INHERITED DISEASES
I n t r a c e l l u l a r  signal-transduction pathways have 
central roles in processes such as growth, development, 
cellular differentiation, and neurotransmission, Alter­
ations in the levels of various substances involved in 
signal-transduction pathways have profound effects on 
cellular functions, and many inherited diseases are
caused by mutations that affect key components of sig­
naling pathways.1
There are two major signal-transduction pathways, 
one using cyclic AMP (cAMP) and the other diacylglyc- 
erol. Each pathway is characterized by its specific pro­
tein kinase, protein kinase A and protein kinase C, re­
spectively. The fine modulation of gene expression is 
achieved by the complex interactions between mem­
brane receptors and the cytoplasmic constituents of 
cells. Among these constituents, the products of onco-
